- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (mnc pharma)
- GSK PHARMA
GSK PHARMA Share Price 
(GLXO)
Here is the latest stock price and chart of GSK Pharma. For more details, see the GSK Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Apr 24, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)2,381.00 | Open (Rs) 2,404.05 | High (Rs) 2,412.00 | Low (Rs) 2,370.00 |
| % Change-1.62 | Volume 1,512 | Value (Rs) 3,609,593 | 52-Week H/L 2,700.00 / 2,040.00 |
| Live NSE Quotes | Apr 24, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)2,385.45 | Open (Rs) 2,414.20 | High (Rs) 2,419.00 | Low (Rs) 2,371.00 |
| % Change-1.37 | Volume 8,291 | Value (Rs) 19,809,912 | 52-Week H/L 2,700.00 / 2,020.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 38.06 | P/E Ratio (x) 62.55 | Market Cap (Rs m) 201,670.70 | P/BV (x) 10.05 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
GSK PHARMA Share Price Today:
GSK PHARMA last traded price was down 1.6% to Rs 2,381.0 on the BSE. On the NSE, GSK PHARMA last traded price was down 1.4% to Rs 2,385.5. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.5%. And the benchmark S&P BSE SENSEX was at 34,616.6 (up 0.5%).
Over the last 30 days, the GSK PHARMA share price is up 11.1%. And over the last one year, GSK PHARMA share price is down 7.6%.
|
| |
Today's Market
Rural India Powering Bikes, Crude Oil Woes and Top Stocks in Action(Pre-Open)
On Tuesday, share markets in India opened on a firm note, remained rangebound and ended the day on a strong footing.
Related Views On News
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)
Nov 20, 2017The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.
Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)
Nov 13, 2017Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.
More Views on NewsMost Popular
Why India is Short of Cash Again(Vivek Kaul's Diary)
Apr 19, 2018It is basically a supply problem with not enough currency going around in the financial system.
A Sure Shot Way to Predict a Multibagger Stock(The 5 Minute Wrapup)
Apr 17, 2018The imaginary stock price of IIM Ahmedabad could have rivalled the returns from Titan and Asian Paints thanks to its enormous pricing power.
Why Buffett Would Scowl at My Latest Recommendation...(Smart Contrarian)
Apr 18, 2018Warren Buffett's advice that may not be so relevant in these dynamic times, and could do investors more damage than good when taken at the face value.
This is How a Smart Robo-Advisor can Help You Chart Your Asset Allocation...(Outside View)
Apr 16, 2018PersonalFN explains how a dependable robo-advisory platform can help you create your personalized asset allocation plan
How Retail Investors Often Dump the Best Buying Opportunities(Chart Of The Day)
Apr 16, 2018A journey into how retail investors have invested since the turn of the millennium and why I don't want to do repeat that mistake ever again...
More|
| |
TRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA 8-QTR ANALYSIS
COMPARE GSK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.